13F Holdings
中文EN

CTSO Cytosorbents Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1175151 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.1%
TTM net income YoY-84.6%
TTM EPS YoY-61.1%
Revenue 3-yr CAGR0.8%
Net income 3-yr CAGR—

Margins

Gross margin71.6%
Operating margin-34.7%
Net margin-48.9%
FCF margin-25.0%
EBITDA margin-32.1%

Returns

ROE-336.2%
ROA-42.4%
ROIC (approx.)-73.4%
Asset turnover0.87x

Leverage & solvency

Liabilities / assets102.0%
Debt / equity—
Current ratio0.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$37.06M$35.59M$31.08M$34.69M$43.17M
Cost of revenue$10.57M$10.71M$9.13M$13.96M$11.05M
Gross profit$26.49M$24.89M$21.95M$20.73M$32.12M
R&D expense——$15.73M$15.12M$16.38M
SG&A expense$35.65M$33.73M$38.31M$34.29M$35.75M
Operating income-$14.75M-$16.45M-$31.95M-$31.52M-$22.74M
Pretax income-$8.60M-$22.41M-$30.06M-$33.91M-$25.29M
Income tax-$401,000-$1.69M-$813,739-$1.09M-$736,003
Net income-$8.20M-$20.72M-$29.25M-$32.81M-$24.56M
EBITDA-$13.52M-$15.12M-$30.49M-$30.64M-$22.01M
EPS (basic)-0.13-0.38-0.65-0.75-0.57
EPS (diluted)-0.13-0.38-0.65-0.75-0.57
Weighted avg. shares (diluted)62.23M54.43M44.66M43.57M43.36M
Balance sheet
Cash & equivalents$6.25M$9.76M$15.62M$23.83M$53.83M
Receivables$7.55M$7.32M$6.06M$5.66M$4.52M
Inventory$5.28M$2.73M$3.38M$3.46M$4.77M
Current assets$20.63M$21.60M$25.40M$33.76M$64.30M
PP&E, net$7.82M$9.00M$10.06M$10.74M$5.15M
Intangibles$3.23M$3.72M$3.91M$4.39M$4.70M
Total assets$44.18M$47.37M$52.96M$63.23M$89.52M
Current liabilities$9.71M$9.82M$14.04M$9.71M$13.69M
Short-term debt——$2.50M——
Long-term debt$16.67M$14.00M$2.54M$5.00M—
Total debt$16.67M$14.00M$5.04M$5.00M—
Total liabilities$38.28M$36.27M$29.48M$27.86M$26.94M
Shareholders' equity$5.90M$11.11M$23.48M$35.37M$62.58M
Net debt$10.42M$4.23M-$10.57M-$18.83M—
Shares outstanding62.80M54.83M54.24M43.64M43.64M
Cash flow statement
Operating cash flow-$12.38M-$14.43M-$21.66M-$28.23M-$14.01M
Capital expenditure$164,000$284,000$538,115$6.09M$3.64M
Free cash flow-$12.54M-$14.71M-$22.19M-$34.32M-$17.65M
Investing cash flow-$415,000-$669,000-$936,236-$6.46M-$4.28M
Financing cash flow$9.31M$9.33M$14.47M$4.96M$715,199
Depreciation & amortization$1.23M$1.33M$1.46M$882,621$731,578
Stock-based compensation$2.77M$3.76M$4.16M$3.42M$4.02M

Free plan shows the latest 5 periods; Pro shows all 29 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.